

SQUARE PHARMACEUTICALS LTD.

AND ITS SUBSIDIARY

1ST QUARTER FINANCIAL STATEMENT

CONSOLIDATED STATEMENT OF FINANCIAL POSITION (Unaudited)

As At 30 June 2015

| | 30-06-2015 Taka | 31-03-2015 Taka |
|---|---------------------------|---------------------------|
| ASSETS: | | |
| Non-Current Assets: | 25,597,697,991 | 25,458,986,164 |
| Property, Plant and Equipment-Carrying Value | 18,147,187,159 | 18,009,200,507 |
| Deferred Tax Assets | 72,153,246 | 75,167,249 |
| Capital Work-in-Progress | 87,644,702 | 207,629,864 |
| Investment - Long Term (at Cost) | 233,723,615 | 251,599,097 |
| Investment - Associates Undertaking | 6,158,591,691 | 6,036,139,963 |
| Investment in Marketable Securities (Fair Value) | 898,397,578 | 879,249,484 |
| Current Assets: | 11,041,202,352 | 9,732,170,099 |
| Inventories | 3,661,482,624 | 3,310,086,668 |
| Trade Debtors | 909,320,257 | 894,543,303 |
| Advances, Deposits and Prepayments | 851,965,123 | 750,169,066 |
| Short Term Loan | 1,094,911,442 | 885,185,428 |
| Cash and Cash Equivalents | 4,523,522,906 | 3,892,185,634 |
| TOTAL ASSETS | 36,638,900,343 | 35,191,156,263 |
| SHAREHOLDERS' EQUITY AND LIABILITIES: | | |
| Shareholders' Equity: | 32,914,193,428 | 31,093,302,284 |
| Share Capital | 5,542,991,520 | 5,542,991,520 |
| Share Premium | 2,035,465,000 | 2,035,465,000 |
| General Reserve | 105,878,200 | 105,878,200 |
| Gain on Marketable Securities (Unrealized) | 269,956,093 | 265,332,813 |
| Retained Earnings | 24,959,902,615 | 23,143,634,751 |
| Non Controlling Interest | (1,783,096) | (1,669,864) |
| Non-Current Liabilities: | 1,136,621,102 | 1,550,505,777 |
| Long Term Loans - Secured | 237,069,937 | 659,147,818 |
| Deffered Tax Liability | 899,551,165 | 891,357,959 |
| Current Liabilities: | 2,589,868,909 | 2,549,018,066 |
| Short Term Bank Loans | 2,297,884 | - |
| Long Term Loans-Current Portion | 72,741,061 | 257,154,669 |
| Trade Creditors | 650,776,596 | 254,773,030 |
| Liabilities for Expenses | 98,079,278 | 43,002,246 |
| Liabilities for Other Finance | 1,765,974,090 | 1,994,088,121 |
| TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES | 36,638,900,343 | 35,191,156,263 |
| Net Assets Value (NAV) per share | 59.38 | 56.09 |
| Number of Shares used to compute NAV | 554,299,152 | 554,299,152 |

Sd/-
Samuel S. Chowdhury
Chairman

Sd/-
Ratna Patra
Vice Chairman

Sd/-
Tapan Chowdhury
Managing Director

Sd/-
Md. Kabir Reza
Chief Financial Officer

Sd/-
Khandaker Habibuzzaman
Company Secretary

SQUARE PHARMACEUTICALS LTD.

AND ITS SUBSIDIARY

1ST QUARTER FINANCIAL STATEMENT

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (Unaudited)

For the 1st Quarter Ended 30 June 2015

| | April-June 2015 Taka | April-June 2014 Taka |
|---|----------------------------|----------------------------|
| GROSS TURNOVER | 8,506,693,465 | 7,495,142,439 |
| Less: Value Added Tax | 1,156,495,178 | 991,642,997 |
| NET TURNOVER | 7,350,198,287 | 6,503,499,442 |
| Cost of Goods Sold | (3,874,928,594) | (3,557,558,813) |
| GROSS PROFIT | 3,475,269,693 | 2,945,940,629 |
| Operating Expenses: | (1,350,906,555) | (1,272,334,727) |
| Selling & Distribution Expenses | (1,094,726,344) | (990,272,324) |
| Administrative Expenses | (242,026,553) | (224,676,756) |
| Financial Expenses | (14,153,658) | (57,385,647) |
| PROFIT FROM OPERATIONS | 2,124,363,138 | 1,673,605,902 |
| Other Income | 102,556,066 | 63,904,359 |
| PROFIT BEFORE WPPF | 2,226,919,204 | 1,737,510,261 |
| Allocation for WPPF | (113,506,455) | (98,416,618) |
| PROFIT BEFORE TAX | 2,113,412,749 | 1,639,093,643 |
| Provision for Income Tax | (545,586,546) | (469,047,676) |
| Provision for Deferred Income Tax | (11,207,209) | (9,437,288) |
| PROFIT AFTER TAX | 1,556,618,994 | 1,160,608,679 |
| Profit/(Loss) from Associates Undertaking | 259,535,638 | 227,453,281 |
| PROFIT FOR THE PERIOD | 1,816,154,632 | 1,388,061,960 |
| Other Comprehensive Income: | | |
| Gain/(Loss) on Marketable Securities (Unrealized) | 4,623,280 | (84,208,158) |
| Total Comprehensive Income for the Period | 1,820,777,912 | 1,303,853,802 |
| Profit Attributable to: | | |
| Owners of the Company | 1,816,267,864 | 1,388,886,883 |
| Non Controlling Interest | (113,232) | (824,923) |
| | 1,816,154,632 | 1,388,061,960 |
| Total Comprehensive Income Attributable to: | | |
| Owners of the Company | 1,820,891,144 | 1,304,678,725 |
| Non Controlling Interest | (113,232) | (824,923) |
| | 1,820,777,912 | 1,303,853,802 |
| Earnings Per Share (EPS) | 3.28 | 2.51 |
| Number of Shares used to compute EPS | 554,299,152 | 554,299,152 |

Sd/-
Samuel S. Chowdhury
Chairman

Sd/-
Ratna Patra
Vice Chairman

Sd/-
Tapan Chowdhury
Managing Director

Sd/-
Md. Kabir Reza
Chief Financial Officer

Sd/-
Khandaker Habibuzzaman
Company Secretary

SQUARE PHARMACEUTICALS LTD.

AND ITS SUBSIDIARY

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (Unaudited)

For the 1st Quarter Ended 30 June 2015

| | Share Capital | Share Premium | General Reserve | Tax Holiday Reserve | Gain on Marketable Securities (Unrealized) | Retained Earnings | Non Controlling Interest | Total Taka |
|---|----------------------|----------------------|--------------------|------------------------|--|-----------------------|-----------------------------|-----------------------|
| | Taka | Taka | Taka | Taka | Taka | Taka | Taka | |
| At 31 March 2015 | 5,542,991,520 | 2,035,465,000 | 105,878,200 | - | 265,332,813 | 23,143,634,751 | (1,669,864) | 31,091,632,420 |
| Total Comprehensive Income (Apr'15-Jun'15) | - | - | - | - | 4,623,280 | 1,816,267,864 | (113,232) | 1,820,777,912 |
| At 30 June 2015 | 5,542,991,520 | 2,035,465,000 | 105,878,200 | - | 269,956,093 | 24,959,902,615 | (1,783,096) | 32,912,410,332 |

SQUARE PHARMACEUTICALS LTD.

AND ITS SUBSIDIARY

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (Unaudited)

For the 1st Quarter Ended 30 June 2014

| | Share Capital | Share Premium | General Reserve | Tax Holiday Reserve | Gain on Marketable Securities (Unrealized) | Retained Earnings | Non Controlling Interest | Total Taka |
|--|----------------------|----------------------|--------------------|------------------------|--|-----------------------|-----------------------------|-----------------------|
| | Taka | Taka | Taka | Taka | Taka | Taka | Taka | |
| At 31 March 2014 | 4,819,992,630 | 2,035,465,000 | 105,878,200 | 406,231,702 | 449,255,557 | 18,922,758,840 | 9,369,803 | 26,748,951,732 |
| Adjustment for Merger of Square Cephalosporins Ltd. | - | - | - | - | - | (165,313) | (8,969,803) | (9,135,116) |
| Total Comprehensive Income (Apr'14-Jun'14) | - | - | - | - | (84,208,158) | 1,388,886,883 | (824,923) | 1,303,853,802 |
| At 30 June 2014 | 4,819,992,630 | 2,035,465,000 | 105,878,200 | 406,231,702 | 365,047,399 | 20,311,480,410 | (424,923) | 28,043,670,418 |

Sd/-
Samuel S. Chowdhury
Chairman

Sd/-
Ratna Patra
Vice Chairman

Sd/-
Tapan Chowdhury
Managing Director

Sd/-
Md. Kabir Reza
Chief Financial Officer

Sd/-
Khandaker Habibuzzaman
Company Secretary

SQUARE PHARMACEUTICALS LTD.

AND ITS SUBSIDIARY

1ST QUARTER FINANCIAL STATEMENT

CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited)

For the 1st Quarter Ended 30 June 2015

| | April-June 2015 Taka | April-June 2014 Taka |
|---|-------------------------------------|-------------------------------------|
| Cash Flows From Operating Activities: | | |
| RECEIPTS: | | |
| Collection from Sales | 8,373,839,566 | 7,343,118,363 |
| Others | 36,530,744 | 9,036,514 |
| | 8,410,370,310 | 7,352,154,877 |
| PAYMENTS: | | |
| Purchase of Raw and Packing Materials | 2,613,058,115 | 2,616,366,432 |
| Manufacturing and Operating Expenses | 2,230,456,301 | 2,108,113,246 |
| Value Added Tax | 1,156,495,178 | 991,642,997 |
| Bank Interest | 14,153,658 | 57,385,647 |
| Income Tax | 639,545,480 | 554,450,540 |
| Workers Profit Participation Fund | 29,796,400 | 30,334,880 |
| Others | 494,433 | 16,966,288 |
| | 6,683,999,565 | 6,375,260,030 |
| Net cash provided by operating activities | 1,726,370,745 | 976,894,847 |
| Cash Flows From Investing Activities: | | |
| Purchase of Fixed Assets | (487,573,754) | (285,868,758) |
| Investment in Marketable Securities | (13,627,403) | (47,239,951) |
| Long Term Investment | 17,875,482 | - |
| Short Term Loan | (209,726,014) | 128,306,275 |
| Capital Work-in-Progress | - | (64,973,145) |
| Interest Received | 51,390,747 | 44,157,862 |
| Dividend Received | 150,821,074 | 133,924,196 |
| Net cash used in investing activities | (490,839,868) | (91,693,521) |
| Cash Flows From Financing Activities: | | |
| Long Term Loan Repaid | (606,491,489) | (125,358,950) |
| Short Term Bank Loan Increase/(Decrease) | 2,297,884 | (21,086,943) |
| Net cash provided/(used) by financing activities | (604,193,605) | (146,445,893) |
| Increase in Cash and Cash Equivalents | 631,337,272 | 738,755,433 |
| Cash and Cash Equivalents at the Opening | 3,892,185,634 | 2,162,717,207 |
| Cash and Cash Equivalents at the Closing | 4,523,522,906 | 2,901,472,640 |
| Net Operating Cash Flow per Share (NOCFPS) | 3.11 | 1.76 |
| Number of Shares used to compute NOCFPS | 554,299,152 | 554,299,152 |

Sd/-
Samuel S. Chowdhury
Chairman

Sd/-
Ratna Patra
Vice Chairman

Sd/-
Tapan Chowdhury
Managing Director

Sd/-
Md. Kabir Reza
Chief Financial Officer

Sd/-
Khandaker Habibuzzaman
Company Secretary

SQUARE PHARMACEUTICALS LTD.

1ST QUARTER FINANCIAL STATEMENTS

STATEMENT OF FINANCIAL POSITION (Unaudited)

As at 30 June 2015

| | 30-06-2015 Taka | 31-03-2015 Taka |
|---|---|--|
| ASSETS: | | |
| Non-Current Assets: | | |
| | 21,702,877,235 | 21,614,399,749 |
| Property, Plant and Equipment-Carrying Value | 15,928,329,141 | 15,721,139,105 |
| Capital Work-in-Progress | - | 119,985,162 |
| Investment - Long Term (at Cost) | 4,876,150,516 | 4,894,025,998 |
| Investment in Marketable Securities (Fair Value) | 898,397,578 | 879,249,484 |
| Current Assets: | | |
| | 11,558,370,556 | 9,739,782,495 |
| Inventories | 2,868,564,491 | 2,684,259,324 |
| Trade Debtors | 909,320,257 | 894,543,303 |
| Advances, Deposits and Prepayments | 806,482,397 | 714,842,990 |
| Short Term Loan | 2,530,196,539 | 1,596,661,104 |
| Cash and Cash Equivalents | 4,443,806,872 | 3,849,475,774 |
| TOTAL ASSETS | 33,261,247,791 | 31,354,182,244 |
| SHAREHOLDERS' EQUITY AND LIABILITIES: | | |
| Shareholders' Equity: | | |
| | 29,752,864,728 | 28,031,892,107 |
| Share Capital | 5,542,991,520 | 5,542,991,520 |
| Share Premium | 2,035,465,000 | 2,035,465,000 |
| General Reserve | 105,878,200 | 105,878,200 |
| Gain on Marketable Securities (Unrealized) | 269,956,093 | 265,332,813 |
| Retained Earnings | 21,798,573,915 | 20,082,224,574 |
| Non-Current Liabilities: | | |
| | 922,757,210 | 931,442,176 |
| Long Term Loans - Secured | 23,206,045 | 40,084,217 |
| Deffered Tax Liability | 899,551,165 | 891,357,959 |
| Current Liabilities: | | |
| | 2,585,625,853 | 2,390,847,961 |
| Long Term Loans - Current Portion | 72,741,061 | 81,514,503 |
| Trade Creditors | 645,318,084 | 254,773,030 |
| Liabilities for Expenses | 95,597,848 | 42,958,189 |
| Liabilities for Other Finance | 1,771,968,860 | 2,011,602,239 |
| TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES | 33,261,247,791 | 31,354,182,244 |
| Net Assets Value (NAV) per share | 53.68 | 50.57 |
| Number of Shares used to compute NAV | 554,299,152 | 554,299,152 |
| Sd/- Samuel S. Chowdhury Chairman | Sd/- Ratna Patra Vice Chairman | Sd/- Tapan Chowdhury Managing Director |
| Sd/- Md. Kabir Reza Chief Financial Officer | Sd/- Khandaker Habibuzzaman Company Secretary | |

SQUARE PHARMACEUTICALS LTD.

1ST QUARTER FINANCIAL STATEMENTS

STATEMENT OF COMPREHENSIVE INCOME (Unaudited) For the 1st Quarter Ended 30 June 2015

| | April-June 2015 Taka | April-June 2014 Taka |
|---|----------------------------|----------------------------|
| GROSS TURNOVER | 8,067,038,351 | 7,487,440,719 |
| Less: Value Added Tax | 1,092,336,550 | 990,523,944 |
| NET TURNOVER | 6,974,701,801 | 6,496,916,775 |
| Cost of Goods Sold | (3,623,828,058) | (3,393,808,464) |
| GROSS PROFIT | 3,350,873,743 | 3,103,108,311 |
| Operating Expenses: | (1,331,669,693) | (1,229,787,004) |
| Selling & Distribution Expenses | (1,084,764,406) | (990,272,324) |
| Administrative Expenses | (241,107,589) | (224,676,756) |
| Financial Expenses | (5,797,698) | (14,837,924) |
| PROFIT FROM OPERATIONS | 2,019,204,050 | 1,873,321,307 |
| Other Income | 364,431,498 | 193,427,675 |
| PROFIT BEFORE WPPF | 2,383,635,548 | 2,066,748,982 |
| Allocation for WPPF | (113,506,455) | (98,416,618) |
| PROFIT BEFORE TAX | 2,270,129,093 | 1,968,332,364 |
| Provision for Income Tax | (545,586,546) | (469,047,676) |
| Provision for Deferred Income Tax | (8,193,206) | (9,437,288) |
| PROFIT AFTER TAX FOR THE PERIOD | 1,716,349,341 | 1,489,847,400 |
| Other Comprehensive Income : | | |
| Gain/(Loss) on Marketable Securities (Unrealized) | 4,623,280 | (84,208,158) |
| Total Comprehensive Income for the Period | 1,720,972,621 | 1,405,639,242 |
| Earnings Per Share (EPS) | 3.10 | 2.69 |
| Number of Shares used to compute EPS | 554,299,152 | 554,299,152 |

Sd/-
Samuel S. Chowdhury
Chairman

Sd/-
Md. Kabir Reza
Chief Financial Officer

Sd/-
Ratna Patra
Vice Chairman

Sd/-
Khandaker Habibuzzaman
Company Secretary

Sd/-
Tapan Chowdhury
Managing Director

SQUARE PHARMACEUTICALS LTD.

STATEMENT OF CHANGES IN EQUITY (Unaudited)
For the 1st Quarter Ended 30 June 2015

| | Share Capital Taka | Share Premium Taka | General Reserve Taka | Tax Holiday Reserve Taka | Gain/(Loss) on Marketable Securities (Unrealized) Taka | Retained Earnings Taka | Total Taka |
|---|--------------------------|--------------------------|----------------------------|--------------------------------|--|------------------------------|----------------|
| At 31 March 2015 | 5,542,991,520 | 2,035,465,000 | 105,878,200 | - | 265,332,813 | 20,082,224,574 | 28,031,892,107 |
| Total Comprehensive Income (Apr'2014-Jun'2014) | - | - | - | - | 4,623,280 | 1,716,349,341 | 1,720,972,621 |
| At 30 June 2015 | 5,542,991,520 | 2,035,465,000 | 105,878,200 | - | 269,956,093 | 21,798,573,915 | 29,752,864,728 |

SQUARE PHARMACEUTICALS LTD.

STATEMENT OF CHANGES IN EQUITY (Unaudited)
For the 1st Quarter Ended 30 June 2014

| | Share Capital Taka | Share Premium Taka | General Reserve Taka | Tax Holiday Reserve Taka | Gain/(Loss) on Marketable Securities (Unrealized) Taka | Retained Earnings Taka | Total Taka |
|--|--------------------------|--------------------------|----------------------------|--------------------------------|--|------------------------------|----------------|
| At 31 March 2014 | 4,819,992,630 | 2,035,465,000 | 105,878,200 | - | 417,680,687 | 14,898,500,111 | 22,277,516,628 |
| Transfer for Merger of Square Cephalosporins Ltd. | - | - | - | 284,928,193 | 31,574,870 | 1,324,169,117 | 1,640,672,180 |
| Total Comprehensive Income (Apr'2014-Jun'2014) | - | - | - | - | (84,208,158) | 1,489,847,400 | 1,405,639,242 |
| At 30 June 2014 | 4,819,992,630 | 2,035,465,000 | 105,878,200 | 284,928,193 | 365,047,399 | 17,712,516,628 | 25,323,828,050 |

Sd/-
Samuel S. Chowdhury
Chairman

Sd/-
Ratna Patra
Vice Chairman

Sd/-
Tapan Chowdhury
Managing Director

Sd/-
Md. Kabir Reza
Chief Financial Officer

Sd/-
Khandaker Habibuzzaman
Company Secretary

SQUARE PHARMACEUTICALS LTD.

1ST QUARTER FINANCIAL STATEMENTS

STATEMENT OF CASH FLOWS (Unaudited) For the 1st Quarter Ended 30 June 2015

| | April-June 2015 Taka | April-June 2014 Taka |
|---|------------------------------------|------------------------------------|
| Cash Flows From Operating Activities: | | |
| RECEIPTS: | | |
| Collection from Sales | 7,947,896,301 | 7,332,624,357 |
| Others | 111,505,649 | 15,345,617 |
| | 8,059,401,950 | 7,347,969,974 |
| PAYMENTS: | | |
| Purchase of Raw and Packing Materials | 2,364,999,301 | 2,514,100,915 |
| Manufacturing and Operating Expenses | 2,149,175,544 | 2,012,608,544 |
| Value Added Tax | 1,092,336,550 | 990,523,944 |
| Bank Interest | 5,797,698 | 14,837,924 |
| Income Tax | 638,958,452 | 541,652,961 |
| Workers Profit Participation Fund | 29,796,400 | 30,334,870 |
| Others | 494,433 | 12,265,395 |
| | 6,281,558,378 | 6,116,324,553 |
| Net cash provided by operating activities | 1,777,843,572 | 1,231,645,421 |
| Cash Flows From Investing Activities: | | |
| Purchase of Fixed Assets | (480,601,942) | (284,259,106) |
| Capital Work-in-Progress | - | (64,973,145) |
| Interest Received | 101,207,364 | 44,157,862 |
| Dividend Received | 150,821,074 | 133,924,196 |
| Short Term Loan | (933,535,435) | (212,502,285) |
| Investment in Marketable Securities | (13,627,403) | (47,239,951) |
| Long Term Investment | 17,875,482 | - |
| Net cash used in investing activities | (1,157,860,860) | (430,892,429) |
| Cash Flows From Financing Activities: | | |
| Long Term Loan Repaid | (25,651,614) | (49,960,606) |
| Short Term Bank Loan Repaid | - | (10,902,234) |
| Net cash used in financing activities | (25,651,614) | (60,862,840) |
| Increase in Cash and Cash Equivalents | 594,331,098 | 739,890,152 |
| Cash and Cash Equivalents at the Opening | 3,849,475,774 | 2,152,834,279 |
| Cash and Cash Equivalents at the Closing | 4,443,806,872 | 2,892,724,431 |
| Net Operating Cash Flow per Share (NOCFPS) | 3.21 | 2.22 |
| Number of Shares used to compute NOCFPS | 554,299,152 | 554,299,152 |

Sd/-
Samuel S. Chowdhury
Chairman

Sd/-
Ratna Patra
Vice Chairman

Sd/-
Tapan Chowdhury
Managing Director

Sd/-
Md. Kabir Reza
Chief Financial Officer

Sd/-
Khandaker Habibuzzaman
Company Secretary

SQUARE PHARMACEUTICALS LIMITED
Notes to the Interim Financial Statements
For the period ended June 30, 2015

Basis of preparation of the Interim Financial Statements:

These Financial Statements (They) are unaudited Interim Financial Statements (hereafter 'the Interim Financial Statements') of Square Pharmaceuticals Limited, Company incorporated in Bangladesh under Companies Act 1913, for the quarter ended June 30, 2015 (hereafter 'the Interim Period'). They are prepared in accordance with the International Accounting Standard (IAS 34) 'Interim Financial Reporting'. These Financial Statements should read in conjunction with the Annual Financial Statements as of March 31, 2015, as they provide an update of previously reported information.

The accounting policies and presentation used are consistent with those used in the Annual Financial Statements, except where noted below. Where necessary, the companies have been reclassified or extended from the previously reported Interim Financial Statements to take into account any presentational changes made in the Annual Financial Statements or in these Interim Financial Statements.

The preparation of the Financial Statements requires management to make estimates and assumptions that affect the reported amounts of revenue, expenses, assets, liabilities and disclosure of contingent liabilities at the date of the Interim Financial Statements. If in the future such estimates and assumptions, which are based on management's best judgment at the date of the Interim Financial Statements, deviate from the actual circumstances, the original estimates and assumptions will be modified as appropriate in the period in which the circumstances change.

The company operates in industries where significant seasonal or cyclical variations in total sales are not experienced during the reporting period.

Income tax expense is recognized based upon the best estimate of the weighted average income tax are expected for the reporting period.

Deferred Income Tax Expense is raised for Tk. 8,193,206 for the adjustable temporary difference upto June 30, 2015.

The Board of Directors on its meeting of dated July 14, 2015 proposed dividend for the year ended March 31, 2015 @ 30% Cash and @ 12.5% Bonus. It shall be accounted for after due approval in AGM that to be held on September 16, 2015.

The Company has no reportable operating segments as per requirement of IFRS-8, operating segment.

There is no significant event to the end of the interim period that has to be reflected in the financial statements for the interim period.

The Company did not carry out any related party transaction other than Square Textiles Ltd., Square Hospitals Ltd., Square InformatiX Ltd., Square Formulations Ltd., Square Fashions Ltd. and AEGIS Services Ltd. Balance as of reporting date is given below:

| | | |
|----------------------------|-------------------|---------------|
| | Receivable | |
| - Square Textiles Ltd. | Tk. | 130,476,183 |
| - Square Hospitals Ltd. | Tk. | 39,889,358 |
| - Square Informatix Ltd. | Tk. | 150,705,296 |
| - Square Formulations Ltd. | Tk. | 1,435,285,097 |
| - Square Fashions Ltd. | Tk. | 773,840,605 |
| | Payable | |
| - AEGIS Services Ltd. | Tk. | 332,992 |

Figures have been rounded off to the nearest Taka.

The contingent liabilities of the company is Tk.1,416,677,720 as on June 30, 2015 for opening letters of credit by the banks in favour of foreign suppliers for Raw Materials, Packing Materials and Plant & Machineries.

| | | | | |
|---|--------------------------------------|--|---|---|
| Sd/- Samuel S. Chowdhury Chairman | Sd/- Ratna Patra Vice Chairman | Sd/- Tapan Chowdhury Managing Director | Sd/- Md. Kabir Reza Chief Financial Officer | Sd/- Khandaker Habibuzzaman Company Secretary |
|---|--------------------------------------|--|---|---|